Drug intelligence / Profile preview

Cell2in-IPF

Development stage: Preclinical
Lead developer: Cell2in
Modality: Stem Cell Therapies → Cell Therapies

Overview

Cell2in-IPF is a mesenchymal stem cell (MSC)-based therapy being developed by Cell2in for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The therapy utilizes Cell2in's proprietary FreSHtracer™ technology to select and isolate high-quality MSCs characterized by high intracellular glutathione (GSH) levels. These high-GSH MSCs exhibit potent antifibrotic and anti-inflammatory properties. Preclinical studies have demonstrated that the therapy can suppress the expression of fibrosis-related genes induced by TGF-β and enhance anti-inflammatory responses, thereby targeting the central TGF-β signaling pathway involved in the progression of pulmonary fibrosis.

Other names: Cell2in-TGF-B-cell therapyCell-2in-TGF-B-cell therapyCell 2in-TGF-B-cell therapy

Beyond the preview

Go deeper on Cell2in-IPF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cell2in-IPF.

Explore the full profile